The NICE ADHD health technology assessment: A review and critique

Table 1 Products evaluated by NICE

Trade Name (England)	Active Ingredient	Formulation	Cost/Daily Dose¹	Assumed Total Daily Dose	Daily Dosage Schedule
Dexedrine	Dex amphetamine	Short-acting	₤ 0.43	20 mg/d	2 (-3) times
Ritalin	Methyl phenidate	Short-acting	₤ 0.56	30 mg/d	3 (2–4) times
Equasym	Methyl phenidate	Short-acting	₤ 0.53	30 mg/d	3 (2–4) times
Concerta XL	Methyl phenidate	Long-acting (~12 h)	₤ 1.23	36 mg/d	1 time
Equasym XL	Methyl phenidate	Long-acting (~8 h)	₤ 1.17	30 mg/d	1 time
Strattera	Atomoxetine	Long-acting	₤ 1.95	Irrelevant (flat pricing)	1 (-2) times

¹Acquisition costs of the National Health Service (NHS) in England (net prices, excluding VAT and not accounting for negotiated procurement discounts in some settings), from British National Formulary 51, March 2006; note that individual doses and thus costs may vary. Assumed average doses should not be confused with dose recommendations.

ISSN: 1753-2000